BELLICUM PHARMACEUTICALS INC (BLCM)
US0794814048 - Common Stock
We assign a fundamental rating of 3 out of 10 to BLCM. BLCM was compared to 588 industry peers in the Biotechnology industry. While BLCM seems to be doing ok healthwise, there are quite some concerns on its profitability. BLCM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BLCM has reported negative net income.
In the past year BLCM has reported a negative cash flow from operations.
BLCM had negative earnings in each of the past 5 years.
In the past 5 years BLCM always reported negative operating cash flow.
1.2 Ratios
BLCM has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLCM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BLCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLCM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLCM has more shares outstanding
BLCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -51.30, we must say that BLCM is in the distress zone and has some risk of bankruptcy.
BLCM has a Altman-Z score of -51.30. This is amonst the worse of the industry: BLCM underperforms 92.16% of its industry peers.
BLCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -51.3 |
ROIC/WACCN/A
WACC8.6%
2.3 Liquidity
BLCM has a Current Ratio of 3.65. This indicates that BLCM is financially healthy and has no problem in meeting its short term obligations.
BLCM has a Current ratio of 3.65. This is in the lower half of the industry: BLCM underperforms 61.60% of its industry peers.
BLCM has a Quick Ratio of 3.65. This indicates that BLCM is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.65, BLCM is not doing good in the industry: 60.64% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
The earnings per share for BLCM have decreased strongly by -183.10% in the last year.
Looking at the last year, BLCM shows a very negative growth in Revenue. The Revenue has decreased by -75.68% in the last year.
Measured over the past years, BLCM shows a very strong growth in Revenue. The Revenue has been growing by 51.17% on average per year.
EPS 1Y (TTM)-183.1%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-4%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y-40.55%
Revenue growth 5Y51.17%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 13.54% on average over the next years. This is quite good.
The Revenue is expected to grow by 187.52% on average over the next years. This is a very strong growth
EPS Next Y38.37%
EPS Next 2Y26.89%
EPS Next 3Y19.89%
EPS Next 5Y13.54%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y187.52%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BLCM. In the last year negative earnings were reported.
Also next year BLCM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BLCM's earnings are expected to grow with 19.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.89%
EPS Next 3Y19.89%
5. Dividend
5.1 Amount
No dividends for BLCM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BELLICUM PHARMACEUTICALS INC
NASDAQ:BLCM (6/1/2023, 7:00:02 PM)
After market: 0.6288 +0.01 (+1.09%)0.622
-0.07 (-9.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-183.1%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y38.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y-40.55%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y